Zynerba (ZYNE) may be on to something with its transdermal CBD patch Zygel. The medication, if approved, could supplant GW Pharmaceuticals’ (GWPH) Epidiolex in the market. Zynerba has jumped 17% since news was released of its new patent on Zygel for the treatment of autism spectrum disorder. The news was not entirely unexpected, as the company already holds Zygel patents for the treatment of other diseases. So given the expected nature of this announcement, it’s unclear why the stock jumped so much on the news. More importantly though than the justifiability